[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-444905-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-444905-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","characteristics-of-adolescents-with-uncontrolled-severe-asthma-starting-dupilumab-the-pediasthma-registry-letter","Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab - The PEDIASTHMA Registry - Letter","","Characteristics of adolescents with uncontrolled severe asthma initiating dupilumab were evaluated in the PEDIASTHMA registry (NCT05070663), a 52-week, multicenter, observational, prospective/retrospective real-world study across 15 sites in metropolitan France. Adolescents aged 12–17 years receiving or starting dupilumab were enrolled; after protocol amendment (October 27, 2022), children aged 6–11 years were also included. This interim analysis describes baseline demographic and disease features, quality of life, medical history, asthma history, and treatments at dupilumab initiation, including prior biologic therapy. Data are presented descriptively as mean (SD).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characteristics-of-adolescents-with-uncontrolled-severe-asthma-starting-dupilumab-the-pediasthma-registry-letter/444905/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characteristics-of-adolescents-with-uncontrolled-severe-asthma-starting-dupilumab-the-pediasthma-registry-letter/444905.png","ImageObject",300,407,{"name":42,"@type":43},"SANS","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the PEDIASTHMA registry and what duration does it cover?","Question",{"text":63,"@type":64},"PEDIASTHMA is a 52-week, multicenter observational study with both prospective and retrospective real-world elements conducted at 15 sites across metropolitan France.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who were eligible participants in the interim analysis?",{"text":68,"@type":64},"Adolescents aged 12–17 years who were already treated with or started dupilumab for severe uncontrolled asthma were eligible; after an October 27, 2022 protocol amendment, children aged 6–11 years were also included.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study evaluate when dupilumab is initiated?",{"text":72,"@type":64},"It describes demographic and disease characteristics, quality of life, medical and asthma history, and asthma treatments at dupilumab start, including prior biologic therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},444905,1790992962,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962090760505,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Allergy  \nLETTER  OPEN ACCESS   \nCharacteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry  \nStéphanie Wanin1,2  | Rola Abou Taam3 | Lisa Giovannini Chami4 | Christophe Marguet5 | Jocelyne Just2,6 | Christele Da Silva7 | Jérôme Msihid7 | Olivier Ledanois8 | Rebecca Gall9 | Harry J. Sacks9 | Juby A. Jacob-Nara10 | Capucine Daridon7 | Antoine Deschildre11   \n1Department of Pediatric Allergology, Armand Trousseau University Hospital, Groupe Hospitalier Universitaire, AP-HP Sorbonne University, Paris, France | 2CRESS, Inserm, INRAE, HERA Team, Université Paris Cité, Paris, France | 3Service de Pneumologie et Allergologie Pédiatriques, Hôpital Necker–Enfants Malades, APHP, Université de Paris, Paris, France | 4Service de Pneumo-Allergologie Pédiatrique, Hôpitaux Pédiatriques de Nice  \nCHU-Lenval, Nice, France | 5Department Pediatrics and Adolescent Medicine, Pulmonology, Allergy and CF, UnivRouen Normandie, UMR 1311 Dynamycure, FHU Respire, CHU Rouen, Rouen, France | 6Unité d'Allergologie, Hôpital Américain de Paris, Neuilly sur Seine, France | 7Sanofi, Gentilly, France | 8Sanofi, Paris, France | 9Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA | 10Sanofi, Bridgewater, New Jersey, USA | 11Service de  \nPneumologie et Allergologie Pédiatriques, Hôpital Jeanne de Flandre, Université de Lille, CHU Lille, Lille, France Correspondence: Stéphanie Wanin ([stephanie.wanin@aphp.fr](stephanie.wanin@aphp.fr))  \nReceived: 31 October 2024 | Revised: 1 October 2025 | Accepted: 10 October 2025  \nFunding: This work was supported by Sanofi and Regeneron Pharmaceuticals Inc. [ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT05070663 .  \nKeywords: asthma | asthma treatment | biologics | inflammation | interleukins | pediatrics | quality-of-life  \nTo the Editor,  \nIn France, the prevalence of asthma in children is 9%–10%[1], with 2%–10% of those having severe asthma [2] . Severe asthma in adolescents (age 12–18 years) is characterized by the precocity and accumulation of sensitizations and allergic comorbidities [3] . The French COBRAPed severe asthma cohort reported allergy in 85% of the patients, with high healthcare resource utilization and impaired quality of life [4] . Biologics have revolutionized the management of severe asthma [2], and accurate phenotyping of severe asthma, through assessment of allergic status and eosinophil counts, for example, enables more personalized treatment [5] .  \nDupilumab is a human monoclonal antibody that blocks the shared receptor component for interleukins 4/13, key and central drivers of type 2 inflammation in multiple diseases [6] . It is approved in the European Union for patients aged ≥12years with severe asthma associated with type 2 inflammation and in children aged ≥6years with asthma inadequately controlled with other treatments. However, the characteristics of children who benefit from dupilumab in the real world are not  \nwell understood. PEDIASTHMA (NCT05070663) is a 52-week, multicenter, observational, prospective, retrospective, realworld study conducted at 15 sites across metropolitan France. Adolescents (age 12–17 years) who were already treated with or started dupilumab treatment for severe uncontrolled asthma were eligible to enroll (severe asthma in children is defined as asthma that remains uncontrolled despite optimized treatment with high-dose inhaled corticosteroids [ICS]-long-acting betaagonists [LABA] or requires high-dose ICS-LABA to prevent it from becoming uncontrolled) [7] . After a protocol amendment (October 27, 2022), children (age 6–11 years) were also included in the study. The primary objective of PEDIASTHMA is to describe the characteristics of enrolled children and adolescents, including demographic and disease characteristics, quality of life, medical and asthma history, and treatments for asthma at initiation of dupilumab (including previous treatment with other biologics). This pre-specified interim analysis of ","cbCaiqJx9qgZ4yJ4","https://ap.wps.com/l/cbCaiqJx9qgZ4yJ4","pdf",487833,"English","# Abstract\n# Background and Rationale\n# Study Design and Participants\n# Objectives and Interim Analysis","[{\"question\":\"What is the PEDIASTHMA registry and what duration does it cover?\",\"answer\":\"PEDIASTHMA is a 52-week, multicenter observational study with both prospective and retrospective real-world elements conducted at 15 sites across metropolitan France.\"},{\"question\":\"Who were eligible participants in the interim analysis?\",\"answer\":\"Adolescents aged 12–17 years who were already treated with or started dupilumab for severe uncontrolled asthma were eligible; after an October 27, 2022 protocol amendment, children aged 6–11 years were also included.\"},{\"question\":\"What does the study evaluate when dupilumab is initiated?\",\"answer\":\"It describes demographic and disease characteristics, quality of life, medical and asthma history, and asthma treatments at dupilumab start, including prior biologic therapy.\"}]","Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab - The PEDIASTHMA Registry - Letter | PDF",1790709695,13]